Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Thursday, July 2

I POSTER SESSIONS Track 4156-118

41156 Neurological complications of HIV and cerebrospinal fluid (CSF)
polymerase chain reaction (PCR)
Rustam Al-Shahi*; M. Sadler; M.R. Nelson; B.G. Gazzard, UK
41157 Mycobacterial nucleic acids in tissues of patients with HIV-infection
Beatrice Ninet*; 0. Rutschmann; K. Burkhardt; C. Metral; B. Borisch;
B. Hirschel, Switzerland
41158 Highly sensitive method for amplification of HIV-2 DNA
Florence Damond*; I. Loussert-Ajaka; D. Descamps; S. Matheron;
F. Brun-Vezinet; F. Simon, France
41159 Fluorescent in situ hybridization to HIV-1 using PCR-generated,
single-stranded, subgenomic DNA probes
Brigit Graf*; H. Kuster; E. Schlaepfer Nadal; M. Fischer; R. Cone,
Switzerland
41160 Discrimination between HIV-1 and HIV-2 by PCR ofserologically
double reactive samples
Lilian Walther*; S. Andersson; F. Dias; Z. da Silva; G. Biberfeld,
Sweden
41161 Genotypic analysis of human immunodeficiency virus in Ukraine
Vadim M. Kavsan*; V.A. Grebenjuk;.V. Anoprienko; A.S. Skorokhod;
I.L. Marichev, Ukraine
41162 Diagnosis of Mycobacterium Tuberculosis using Lygase chain reaction
assay (LCR)
Julius Otieno Oyugi*; JO. Ombette; G. Maitha;.0. Bwayo, Kenya
41163 Establishment of HeLa/CD4-LTR-b-Gal stably expressing CCR5 suitable for
infectivity assay ofT- and M-tropic HIV-1,and its application to clinical
isolation and cloning of virus
Masashi Tatsumi*; A. Kojima, Japan
41164 Plasma-concentrations of IL-16, but not of b-chemokines change
uniformly during triple combination-therapy of HIV-1 infection
Klaus Cichutek*; P. Miller; M. Engelstaedter; S. Staszewski; V. Miller;
H.W. Doerr; R. Kurth, Germany
41165 Evaluation of Western blot criteria for confirmation of HIV antibodies
in saliva and urine specimens
Prudencio Martinez; R. Ortiz de Lejarazu; P. Martinez; J.M. Eiros;
A. Rodriques-Torres, Spain
41166 WHO recommendations for HIV testing strategies: Experience of
Mozambique
Guillaure Guiraud*; R. Bastos; S. Tembe; E.V. Chicoville; J.F. Langa,
Mozambique
41167 Hairy Leukoplakia: A clinical, histological, cytological and
immunohistochemical study
Arley Silva Junior*; E.P. Dias; S.M.S. Ferreira, Brazil
41168 False positive enzyme-linked immunosorbent assay for HIV in persons
with autoimmune diseases and macroglobulinemia
Lawrence A. Cone*; R.G. Byrd;J.N. Hirschberg, USA
41169 Comparison of mycobacteria growth indicator tube and LowensteinJensen medium for the recovery of Mycobacterium tuberculosis from
clinical specimens in Senegal
Edgard Adam Macondo*; Cheikh Saad-Bouh Boye; Fatou Ba; Gaye-Diallo
Aissatou; Ndeye Coumba Toure-Kane; Ndiaye Aston Gueye; Souleymane
Mboup, Senegal

41170 Community-acquired bacterial and fungal infections in HIV-positive
patients hospitalized in AIDS Diagnosis andTherapy Center in Warsaw,
Poland
Janusz Stanczak*; E. Czekalska-Lachowicz; G. Skowronska;
U. Komorowska; E. Tobolewska; A. Lipniacki; A. Horban, Poland
41171 Feasibility of HIV rapid test in Mozambique:Technical aspect
Jose-Fernando Langa*; Guillaure Guiraud; S. Tembe; E.V. Chicovele,
Mozambique
41172 Prospective evaluation of patients with AIDS and abdominal surgery
Eduardo Ferat*; G. Guzman-Valdivia; L. Rosales; G. Luna; S. Treviho;
L. Nieto; M. Santoscoy, Mexico
41173 Impact of Human Immunodeficiency Virus type 1 (HIV-1) subtype on
HIV antibody detection in Burkina Faso
Philippe Van De Perre*; Lucile Gautier-Charpentier; O.R. Ouedraogo;
S.A. Simonon; M.N. Meda; D.H. Dahourou; S.R. Soudre; B.F. Barin,
Burkina Faso
41174 Anti-HIV activity, biochemistry,and pharmacokinetics
of b-D-2',3'-didehydro-2',3'-dideoxy-5- fluorocytidine (D-D4FC)
Raymond Schinazi*; L. Ma; J. Shi; D. Liotta; A. Faraj; J.P. Sommadossi,
USA
41175 Cellular pharmacology of the antiviral agents PMPA and PMEA
in vitro and in vivo
Arnold Fridland*; B. Robbins; J. Rodman; C.C. Tsai; N. Bischofberger, USA
41176 The safety,tolerance,pharmacokinetics,and efficacy of PNU-140690,
a new non-peptidic HIV protease inhibitor,in a phase I/Il study
Yenyun Wang*; C.M. Tutton; M.T. Borin; CL. Daenzer; H. Li; R.M. Wurtz;
A.A. Piergies; W.W. Freimuth, USA
41177 Peripheral insulin resistance leading to impaired glucose tolerance in
HIV-1 infected patients treated with protease inhibitors
Ravi K. Walli*; 0. Herfort; G.M. Michl; T. Demant; S. Maus; C Dieterle;
F.D. Geobel, Germany
41178 Triple combination therapy and change in peripheral blood T-cell subset
composition during asymptomatic HIV-infection
Leslie R. Bisset*; Milos Opravil;R. Con; W Huber;M. Battegay; P Vernazza;
RJ. Grob; R. Luethy, Switzerland
41179 Dynamics of CD4+ T cell recovery in a large cohort treated with highly
active anti retroviral therapies at advanced stages of HIV disease
Marc Renaud*; H.M. Ait; C. Katlama; V. Calvez; A. Mallet; P. Debre;
B. Autran, France
41180 Long term suppression of HIV with a simple, non toxic, inexpensive
combination of didanosine (ddl) plus hydroxyurea (HU)
Elena Seminari*; R. Maserati; F. Lori; F. Alberici;J. Lisziewicz, Italy
41181 S-1153, a new nonnucleoside reverse transcriptase inhibitor of HIV-1
Tamio Fujiwara*; A. Sato; M. EI-Farrash; Y. Wu3; L. Chen; M. Hatanaka;
Y. Hinuma, Japan
41182 Specific inhibition ofT-lymphocyte- and macrophage-tropic HIV entry
by a V3 loop mimicking pseudopeptide that binds cell-surface proteins
Nabila Seddiki*; E. Dam; S. Nisole; C Callebaut; B. Krust; J.P. Briand;
A.G. Hovanessian, France
41183 Anti-HIV activity of AMD3465, a novel antagonist of the CXCR4 receptor
Jose A. Est *; C Cabrera; G. Henson; B. Clotet; G. Bridger; D. Schols;

E. De Clerco, Spain

188

12th World AIDS Conference Geneva